Q1 2024 Media Update

First-quarter performance as expected

• Group sales at 13.765 billion euros (Fx & p adj. minus 0.6 percent), currency headwinds of 525 million euros
• EBITDA before special items falls 1.3 percent to 4.412 billion euros
• Sales and earnings down at Crop Science and Consumer Health
• Pharmaceuticals posts higher sales and earnings
• Core earnings per share at 2.82 euros (minus 4.4 percent)
• Net income at 2.0 billion euros
• Free cash flow at minus 2.626 billion euros
• Currency-adjusted Group outlook confirmed  

NEWS RELEASE